BEZ235 or NVP-BEZ235 is an imidazoquinoline derivative and PI3K inhibitor being investigated as a possible cancer treatment.It has been shown to be toxic to Waldenström’s macroglobulinemia cells.It was the first PI3K inhibitor to enter clinical trials in 2006 (primary outcome results due in 2010).
This page contains content from the copyrighted Wikipedia article "BEZ235"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
